Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $5.25 per share, before underwriting discounts. The offering is expected to close on or about January 22, 2018, subject to customary closing conditions. In addition, Arrowhead has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less the underwriting discount. Jefferies LLC and Barclays Capital Inc. are acting as bookrunning managers for the offering, Cantor Fitzgerald & Co. is acting as passive joint bookrunner for the offering and Chardan and B. Riley FBR, Inc. are acting as co-managers for the offering.

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

Pasadena, CA | Posted on January 18th, 2018

Gross offering proceeds will be approximately $52.5 million, before deducting underwriting discounts and commissions and offering expenses. Arrowhead intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used for the acquisition of complementary businesses, products and technologies, or for other strategic purposes.

A shelf registration statement on Form S-3 (File No. 333-214315) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the final prospectus supplement may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at or from Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-888-603-5847, or email: .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding our expectations with respect to our proposed public offering. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, and other SEC filings discuss some of the important risk factors that may affect our ability to achieve the anticipated results, as well as our business, results of operations and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements. Additionally, Arrowhead disclaims any intent to update these forward-looking statements to reflect subsequent developments.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Birth of a hybrid: High-temperature synthesis under pressure helps to combine properties of metals and ceramics December 15th, 2018

The role of lipid nanoparticles and its surface modification in reaching the brain: This article by Dr. Manoli Igartua et al. is published in Current Drug Delivery, Volume 15, Issue 9, 2018 December 14th, 2018

Researchers use jiggly Jell-O to make powerful new hydrogen fuel catalyst: The inexpensive new material can split water just as efficiently as costly platinum December 14th, 2018

IMDEA Nanociencia and Universidad Autónoma de Madrid researchers have demonstrated that graphene deposited on a metal surface promotes an unusual chemical reaction that would hardly take place under noncatalyzed conditions. December 14th, 2018

Possible Futures

Birth of a hybrid: High-temperature synthesis under pressure helps to combine properties of metals and ceramics December 15th, 2018

Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN): This article by Dr. Sanjay Singh et al. is published in Current Drug Delivery, Volume 15 , Issue 8 , 2018 December 14th, 2018

Researchers use jiggly Jell-O to make powerful new hydrogen fuel catalyst: The inexpensive new material can split water just as efficiently as costly platinum December 14th, 2018

IMDEA Nanociencia and Universidad Autónoma de Madrid researchers have demonstrated that graphene deposited on a metal surface promotes an unusual chemical reaction that would hardly take place under noncatalyzed conditions. December 14th, 2018

Investments/IPO's/Splits

180 Degree Capital Corp.’s Portfolio Company, TheStreet, Inc., Agrees to Sell Its Institutional Business Units to Euromoney Institutional Investor PLC for $87.3 Million December 6th, 2018

These small caps are tapping a graphene market that has more than doubled in a year December 1st, 2018

Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen October 31st, 2018

180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.81 as of September 30, 2018; a Decrease of 3.4% From June 30, 2018 October 29th, 2018

Nanomedicine

The role of lipid nanoparticles and its surface modification in reaching the brain: This article by Dr. Manoli Igartua et al. is published in Current Drug Delivery, Volume 15, Issue 9, 2018 December 14th, 2018

A summary of electrospun nanofibers as drug delivery system: This article by Dr. José Manuel Cornejo Bravo et al. is published in Current Drug Delivery, Volume 15 , Issue 10 , 2018 December 14th, 2018

Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN): This article by Dr. Sanjay Singh et al. is published in Current Drug Delivery, Volume 15 , Issue 8 , 2018 December 14th, 2018

Collagen nanofibrils in mammalian tissues get stronger with exercise December 14th, 2018

Announcements

Birth of a hybrid: High-temperature synthesis under pressure helps to combine properties of metals and ceramics December 15th, 2018

The role of lipid nanoparticles and its surface modification in reaching the brain: This article by Dr. Manoli Igartua et al. is published in Current Drug Delivery, Volume 15, Issue 9, 2018 December 14th, 2018

A summary of electrospun nanofibers as drug delivery system: This article by Dr. José Manuel Cornejo Bravo et al. is published in Current Drug Delivery, Volume 15 , Issue 10 , 2018 December 14th, 2018

Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN): This article by Dr. Sanjay Singh et al. is published in Current Drug Delivery, Volume 15 , Issue 8 , 2018 December 14th, 2018

Nanobiotechnology

The role of lipid nanoparticles and its surface modification in reaching the brain: This article by Dr. Manoli Igartua et al. is published in Current Drug Delivery, Volume 15, Issue 9, 2018 December 14th, 2018

A summary of electrospun nanofibers as drug delivery system: This article by Dr. José Manuel Cornejo Bravo et al. is published in Current Drug Delivery, Volume 15 , Issue 10 , 2018 December 14th, 2018

Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN): This article by Dr. Sanjay Singh et al. is published in Current Drug Delivery, Volume 15 , Issue 8 , 2018 December 14th, 2018

Collagen nanofibrils in mammalian tissues get stronger with exercise December 14th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project